Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease.

J Bauditz, J Haemling, M Ortner, H Lochs, A Raedler, S Schreiber

Charité University Hospital, 4th Department of Medicine/Mucosal, Berlin, Germany.

BACKGROUND: In Crohn's disease, inflammation is presumably sustained by an increased production of proinflammatory cytokines, in particular tumour necrosis factor alpha (TNF alpha) and interleukin 1 beta (IL 1 beta). TNF alpha can induce a host of cellular effector events resulting in perpetuation of the inflammatory process. In vivo studies with anti-TNF alpha antibody treatment have led to impressive clinical results. AIMS: To investigate whether treatment with the TNF alpha inhibitor oxpentifylline results in clinical improvement in corticosteroid dependent chronic active Crohn's disease. METHODS: Sixteen Crohn's disease patients received oxpentifylline 400 mg four times a day in a four week open label study. RESULTS: Blockade of TNF alpha production in 16 patients with corticosteroid dependent Crohn's disease did not improve the clinical disease activity (CDAI mean (SEM) 188.75 (5.65) versus 185.13 (10.87) or the endoscopic degree of inflammation (CDEIS 14.9 (2.87) versus 14.8 (2.27) or laboratory parameters. CONCLUSIONS: In this study, use of the TNF alpha inhibitor oxpentifylline does not improve inflammation in Crohn's disease. This finding suggests that there may be more key mediators than only TNF alpha in the inflammatory process in Crohn's disease.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Oxpentifylline, tumour necrosis factor-alpha and Crohn's disease.

T T MacDonald
Gut 1997 40: 559. [PDF]

This article has been cited by other articles:

• Sands, B. E., Kaplan, G. G. (2007). The Role of TNF{alpha} in Ulcerative Colitis. J Clin Pharmacol 47: 930-941 [Abstract] [Full Text]  
• Gordon, J N, Trebble, T M, Ellis, R D, Duncan, H D, Johns, T, Goggin, P M (2005). Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 54: 540-545 [Abstract] [Full Text]  
• Di Sabatino, A, Ciccocioppo, R, Cinque, B, Millimaggi, D, Morera, R, Ricevuti, L, Cifone, M G, Corazza, G R (2004). Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut 53: 70-77 [Abstract] [Full Text]  
• van Deventer, S J H (2002). Small therapeutic molecules for the treatment of inflammatory bowel disease. Gut 50: iii47-53 [Abstract] [Full Text]  
• Bauditz, J, Wedel, S, Lochs, H (2002). Thalidomide reduces tumour necrosis factor {alpha} and interleukin 12 production in patients with chronic active Crohn's disease. Gut 50: 196-200 [Abstract] [Full Text]  
• SCHREIBER, S, HAMPE, J, EICKHOFF, H, LEHRACH, H (2000). Functional genomics in gastroenterology. Gut 47: 601-607 [Full Text]  
• Hartmann, G., Bidlingmaier, C., Siegmund, B., Albrich, S., Schulze, J., Tschoep, K., Eigler, A., Lehr, H. A., Endres, S. (2000). Specific Type IV Phosphodiesterase Inhibitor Rolipram Mitigates Experimental Colitis in Mice. J. Pharmacol. Exp. Ther. 292: 22-30 [Abstract] [Full Text]